Free Trial
NYSEAMERICAN:CCEL

Cryo-Cell International (CCEL) Stock Price, News & Analysis

Cryo-Cell International logo
$7.27
-0.04 (-0.55%)
(As of 10/31/2024 ET)

About Cryo-Cell International Stock (NYSEAMERICAN:CCEL)

Key Stats

Today's Range
$7.20
$8.10
50-Day Range
N/A
52-Week Range
$3.67
$9.50
Volume
98,093 shs
Average Volume
9,584 shs
Market Capitalization
$58.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Cryo-Cell International Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
19th Percentile Overall Score

CCEL MarketRank™: 

Cryo-Cell International scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cryo-Cell International is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cryo-Cell International is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.27% of the float of Cryo-Cell International has been sold short.
  • Short Interest Ratio / Days to Cover

    Cryo-Cell International has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cryo-Cell International has recently decreased by 29.27%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cryo-Cell International does not currently pay a dividend.

  • Dividend Growth

    Cryo-Cell International does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.27% of the float of Cryo-Cell International has been sold short.
  • Short Interest Ratio / Days to Cover

    Cryo-Cell International has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cryo-Cell International has recently decreased by 29.27%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cryo-Cell International has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Cryo-Cell International this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Cryo-Cell International insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    33.80% of the stock of Cryo-Cell International is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 10.44% of the stock of Cryo-Cell International is held by institutions.

  • Read more about Cryo-Cell International's insider trading history.
Receive CCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cryo-Cell International and its competitors with MarketBeat's FREE daily newsletter.

CCEL Stock News Headlines

CRYO-CELL International, Inc. trading resumes
CRYO-CELL International, Inc. trading halted, volatility trading pause
The real reason Elon is fully endorsing Trump
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
Cryo-Cell International Inc CCEL
Cryo-Cell International Inc
See More Headlines

CCEL Stock Analysis - Frequently Asked Questions

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) issued its quarterly earnings data on Tuesday, October, 15th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.11. The company had revenue of $8.07 million for the quarter. Cryo-Cell International had a negative net margin of 29.38% and a negative trailing twelve-month return on equity of 49.94%.

Shares of CCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cryo-Cell International investors own include Meta Platforms (META), Alimera Sciences (ALIM), Catalyst Biosciences (CBIO), iClick Interactive Asia Group (ICLK), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX) and Aspen Group (ASPU).

Company Calendar

Last Earnings
10/15/2024
Today
10/31/2024
Fiscal Year End
11/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
Healthcare
Current Symbol
NYSEAMERICAN:CCEL
Employees
90
Year Founded
N/A

Profitability

Net Income
$-9,520,000.00
Pretax Margin
-40.01%

Debt

Sales & Book Value

Annual Sales
$31.34 million
Cash Flow
$0.74 per share
Book Value
($1.33) per share

Miscellaneous

Free Float
5,337,000
Market Cap
$58.44 million
Optionable
Not Optionable
Beta
0.45

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NYSEAMERICAN:CCEL) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners